Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
AstraZeneca
McKinsey
McKesson

Last Updated: May 17, 2022

Investigational Drug Information for AZD3293


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for AZD3293?

AZD3293 is an investigational drug.

There have been 15 clinical trials for AZD3293. The most recent clinical trial was a Phase 1 trial, which was initiated on March 15th 2017.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Eli Lilly and Company, and Parexel.

There are fourteen US patents protecting this investigational drug and one hundred and eighty-one international patents.

Recent Clinical Trials for AZD3293
TitleSponsorPhase
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaAstraZenecaPhase 3
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaEli Lilly and CompanyPhase 3
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With RosuvastatinAstraZenecaPhase 1

See all AZD3293 clinical trials

Clinical Trial Summary for AZD3293

Top disease conditions for AZD3293
Top clinical trial sponsors for AZD3293

See all AZD3293 clinical trials

US Patents for AZD3293

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD3293 See Plans and Pricing Compounds, compositions and methods Denali Therapeutics Inc. (South San Francisco, CA) See Plans and Pricing
AZD3293 See Plans and Pricing Compositions and methods for treating HIV-associated neurocognitive disorders THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL) See Plans and Pricing
AZD3293 See Plans and Pricing Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertalje, SE) See Plans and Pricing
AZD3293 See Plans and Pricing Camsylate salt ASTRAZENECA AB (Sodertalje, SE) See Plans and Pricing
AZD3293 See Plans and Pricing Compounds, compositions and methods Denali Therapeutics Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD3293

Drugname Country Document Number Estimated Expiration Related US Patent
AZD3293 Argentina AR107537 2036-02-05 See Plans and Pricing
AZD3293 Argentina AR115780 2036-02-05 See Plans and Pricing
AZD3293 Australia AU2017213628 2036-02-05 See Plans and Pricing
AZD3293 Brazil BR112018015410 2036-02-05 See Plans and Pricing
AZD3293 Canada CA3012832 2036-02-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.